Manufacturing

March 20, 2024

FDA's approval makes Orchard Therapeutics' Lenmeldy (atidarsagene autotemcel) the first gene therapy approved to treat pediatric metachromatic leukodystrophy in the US.

March 18, 2024

Cellares CEO Fabian Gerlinghaus discusses the nuts and bolts of counterflow centrifugal elutriation and electroporation innovations and optimization, while hinting at big news on future release testing of products, as a product itself.

March 16, 2024

Mapp Biopharmaceutical will use ProBioGen’s GlymaxX technology for the development of an afucosylated antibody against Marburg virus infection

March 16, 2024

Misalignment around liquid filtration requirements and contamination control assurance still persist despite the revisions to Annex 1.

March 16, 2024

The evolution of therapeutic modalities drives the adoption of single-use technologies.

March 15, 2024

Quality-by-design risk assessment workflows can be laborious and have limited capacity to connect with vast volumes of prior knowledge generated by organizations. Their digital transformation can improve efficiency, reduce human errors, and facilitate integration within a much broader digital ecosystem.

March 14, 2024

In a new manufacturing pact, Chime Biologics will produce DT-7012, Domain Therapeutics' antibody candidate for treating cancer that will soon be entering Phase I studies.

March 14, 2024

Webinar Date/Time: Wed, Apr 24, 2024 11:00 AM EDT

March 12, 2024

In an interview, Fabian Gerlinghaus of Cellares outlines a paradigm change in both hardware and software, regulatory expansions, and some positive cost outcomes for the CGT field.

March 12, 2024

The Cell Shuttle platform will manufacture cell therapies for its first clinical trials by the end of the year.